Loading market dashboard
LMP Capital and Income Fund Inc.
SCDFinancial ServicesNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9% plus yield and nearly 7.5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its
NEW YORK--(BUSINESS WIRE)--Category: Fund Announcement.
Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleinopathies and other CNS diseases. Among CNS unmet conditions, brain metastasis (BM) remains a lethal progression of the primary cancer in urgent need of novel and effective therapies.
Allspring Global Investments Holdings LLC purchased a new position in LMP Capital and Income Fund Inc. (NYSE: SCD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,497 shares of the real estate investment trust's stock, valued at approximately $970,000. Other institutional
98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary formulation of Aramchol which targets the brain.
LMP Capital & Income Fund (SCD) offers a 9.63% yield, higher than broad equity indices and most peers, with a sustainable distribution profile. SCD's overweight energy allocation (14.05%) positions it for potential outperformance amid elevated oil prices and ongoing geopolitical tensions. The fund's NAV per share has risen 12.49% over three years, indicating strong distribution coverage and prudent management.
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data
